Cardium Therapeutics Inc. (CXM)
-NYSE MKT | Prev Close: | 0.08 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 0.40 |
|---|
| Beta: | 3.88 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.06 - 0.26 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 537,580 |
|---|
| Market Cap: | 11.00M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.07 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013PR Newswire(Thu, Jun 6)
- Form 10 K for Cardium TherapeuticsWILink(Tue, May 28)
- Cardium Announces Favorable Recommendations From ISS And Glass Lewis For Annual Meeting ProposalsPR Newswire(Tue, May 28)
- CARDIUM THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Tue, May 21)
- CARDIUM THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- Cardium Presents First Quarter 2013 Financial Results And Reports On Recent DevelopmentsPR Newswire(Wed, May 15)
- CARDIUM THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 6)
- Cardium Announces Generx Publication In Molecular TherapyPR Newswire(Thu, May 2)
- Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 MeetingPR Newswire(Tue, Apr 30)
- CARDIUM THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, Apr 11)
- Cardium Presents Year-End 2012 Financial Results And Recent DevelopmentsPR Newswire(Fri, Apr 5)
- Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing CompliancePR Newswire(Fri, Apr 5)
- CARDIUM THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles ofEDGAR Online(Fri, Apr 5)
- CARDIUM THERAPEUTICS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Fri, Mar 15)
- Cardium Receives ISO Certification for ExcellagenPR Newswire(Thu, Mar 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 8.06 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.05 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.01 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cardium Therapeutics, Inc., a medical technology company, engages in the development and commercialization of products and devices for cardiovascular and ischemic diseases, wound healing, and tissue repair.
View More 
1.35%